Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

113.73 +1.84 (+1.64%)
Streaming Delayed Price Updated: 11:59 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
News Is Noise
Via Talk Markets
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Gilead Sciences Unusual Options Activity For September 20
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment. 
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
What the Options Market Tells Us About Gilead Sciences
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Unveiling 10 Analyst Insights On Gilead Sciences
Via Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Why Gilead Sciences Stock Thrashed the Market Today
In drug development, solid performance in large-scale clinical trials is crucial. 
Via The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by... 
Via Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Four Stocks To Watch This Week - Monday, Sept 9
Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. 
Via Talk Markets
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals. 
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.